FIELD: medicine.
SUBSTANCE: present invention relates to a method for the treatment of cancer in a patient who needs treatment. The method includes administration to the patient of therapeutically effective amount of a compound having the formula 
or its pharmaceutically acceptable salt in a combination with therapeutically effective amount of EGFR inhibitor or its pharmaceutically acceptable salt, where EGFR inhibitor is Osimertinib or its pharmaceutically acceptable salt, and where cancer is lung cancer.
EFFECT: invention provides a synergetic response in a patient who needs treatment of cancer.
11 cl, 20 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIRAL DIARYL MACROCYCLES AND USE THEREOF | 2016 |
|
RU2728579C2 |
| CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | 2016 |
|
RU2732405C2 |
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT | 2018 |
|
RU2805355C2 |
| BENZO[b]THIOPHENE STING AGONISTS FOR TREATMENT OF CANCER | 2018 |
|
RU2771811C2 |
| METHOD FOR ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY STRENGTHENING | 2011 |
|
RU2627660C2 |
| PYRROLO[2,3-b]PYRIDINE DERIVATIVES INHIBITING ACTIVITY OF ANTI-APOPTOTIC Bcl-2 PROTEINS | 2011 |
|
RU2567857C2 |
| BI- AND POLYCYCLIC SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES, USEFUL AS RHO-KINASE INHIBITORS | 2009 |
|
RU2532481C2 |
| HUMAN EZH2 INHIBITORS AND METHODS FOR USE THEREOF | 2013 |
|
RU2704445C2 |
| 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | 2021 |
|
RU2825312C1 |
| BICYCLIC COMPOUNDS AS PD1/PD-L1 INTERACTION/ACTIVATION INHIBITORS | 2019 |
|
RU2777980C2 |
